Abnormal analyte preeclampsia: do the second-trimester maternal serum analytes help differentiate preeclampsia subtypes?

Abstract

ObjectiveTo determine if serum screen analytes identify preeclamptic patients at risk for small-for-gestational-age newborns, maternal laboratory abnormalities and preterm delivery (<37 weeks gestation).Study DesignUsing a retrospective cohort of 102 preeclamptic patients, associations between serum screen analytes and newborn birth-weight percentile, gestational age (GA) at delivery and maternal pre-delivery laboratory abnormalities were evaluated using correlation coefficients and local polynomial regression.ResultsInhibin-A and MS-AFP were inversely correlated with newborn birth weight %ile (-0.27, p=0.006; -0.35, p=0.00004) and delivery GA (r = -0.42, p<0.0001; r = -0.26, p = 0.008) and positively correlated with pre-delivery AST (r = 0.22, p=0.03; r=0.21, p=0.04) and LDH (r=0.33, p=0.0007; r= 0.29, p=0.004). A positive correlation was noted between both second trimester β-HCG and Estriol and maternal pre-delivery creatinine (0.28, p=0.004; 0.4, p < 0.0001, respectively).100% of patients with ≥2 abnormal analytes delivered prior to 37 weeks gestation.ConclusionsPreeclamptic patients with abnormal serum screen analytes are more likely to have SGA newborns, deliver preterm and have pre-delivery laboratory abnormalities.